Polymorphism of TNF gene in acute coronary syndrome patients: data from the registries ORACLE I and ORACLE II

Aim. To analyze possible association of the risk of adverse outcomes development in patients post acute coronary episode (ACS), with the polymorphism of gene TNF.

Material and methods. To the study, patients included, that were under observation in 2 registry studies ORACLE I and II (Exacerbation of coronary heart disease: logic-probability ways of course prediction and treatment optimization). In overall, 2012 ACS patients assessed. Mean age 64,7±12,69 y.o. There were 1205 males (59,8%) and 807 females (40,2%). 741 patients (36,8%) included with ST elevation ACS, 1271 (63,2%) — with non-ST elevation ACS. Follow-up started at the 10th day from clinical stabilization. Clinical outcomes were gathered based on phone calls with the patients and their relatives, as during the outpatient office visits. Assessment of polymorphisms of gene TNF done with PCR.

Results. In the assessed group, the frequency of alleles and gene TNF genotypes were measured: 18 patients carried genotype АА (0,9%), 561 patients — AG (279%), 1433 — GG (71,2%). In those with the allele А gene TNF, more commonly the episodes of SCD were noted (9,8% comparing to 6,6% of GG carriers, p<0,001); rate of non-cardiac death did not differ significantly (3,5% and 3,1%, respectively). There were no significant differences in the rate of fatal and non-fatal strokes, number of non-complicated cases of peripheral atherosclerosis. In the group of patients with allele A, there were more common the repeated ACS episodes (21,4% vs 12,8% in GG carriers, p<0,001). The rate of repeated after discharge interventions did not differ significantly. Independent factors for any adverse outcome (death, ACS, stroke, complicated atherosclerosis, repeated coronary interventions) were myocardial infarction (OR 1,235 (1,041-1,464)) and heart failure (OR 1,22 (1,02-1,44)) in anamnesis, decreased GFR (OR 1,04 (0,87-1,43)) and carriage of АА and AG gene TNF (OR 1,35 (1,14-1,60)).

Conclusion. Carriage of the rare A allele of polymorphic marker G(-308)A gene TNF is associated with more common development of adverse outcomes in patients after exacerbation of CHD.

1. Sidorenko BA, Dorofeeva EV, Dokina ED, et al. Prevention of cardiovascular complications and incidence of myocardial infarction and stroke in patients under long-term polyclinic observation. Kremleskaya Medicina.Clinichesky vestnik. 2017(1 ):55-60. (In Russ.)

2. Zhang P, Wu X, Li G, et al. Tumor necrosis factor-alpha gene polymorphisms and susceptibility to ischemic heart disease: A systematic review and meta-analysis. Medicine (Baltimore). 2017 Apr;96(14):e6569. doi:10.1097/MD.0000000000006569.

3. Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol. 2016 Jan;12(1):49-62. doi:10.1038/nrrheum.2015.169.

4. Zateyshchikov DA, Guz IO, Evdokimova MA, et al. Treatment of patients who underwent acute coronary syndrome, according to the Russian multicenter prospective observational study. Pharmateca. 2009;12:109-13. (In Russ.)

5. Averkova AO, Koroleva OS, Zubova EA, et al. Acute coronary syndrome in young patients with familial hypercholesterolemia based on the results of ORACUL II observation trial. Medical news of North Caucasus. 2017;12(1):5-8. (In Russ.)

6. Luna GI, da Silva IC, Sanchez MN. Association between -308G/A TNFA Polymorphism and Susceptibility to Type 2 Diabetes Mellitus: A Systematic Review. J Diabetes Res. 2016;2016:6309484.

7. Dabek J, Swiderski R, Glogowska-Ligus J, et al. Transcriptional activity of tumour necrosis factor alpha (TNF-alpha) in patients with subclinical coronary atherosclerosis — preliminary results. Folia Biol (Praha). 2012;58(5):209-14.

8. Sandoval-Pinto E, Padilla-Gutierrez JR, Valdes-Alvarado E, et al. Association of the 1031T>C polymorphism and soluble TNF-alpha levels with Acute Coronary Syndrome. Cytokine. 2016;78:37-43.

9. Sobti RC, Kler R, Sharma YP, Talwar KK, Singh N. Risk of obesity and type 2 diabetes with tumor necrosis factor-а 308G/A gene polymorphism in metabolic syndrome and coronary artery disease subjects. Mol Cell Biochem. 2012 Jan;360(1-2):1-7. doi:10.1007/s11010-011-0917-z.

10. Babu BM, Reddy BP, Priya VH, et al. Cytokine gene polymorphisms in the susceptibility to acute coronary syndrome. Genet Test Mol Biomarkers. 2012;16(5):359-65.

11. Dedoussis GV, Panagiotakos DB, Vidra NV, et al. Association between TNF-alpha -308G>A polymorphism and the development of acute coronary syndromes in Greek subjects: the CARDIO2000-GENE Study. Genet Med. 2005;7(6):411-6.

12. Huangfu F, Zhao X, Wang X, et al. There is no association between TNF-alpha gene polymorphisms and the risk of coronary artery heart disease: a meta-analysis. J Cardiovasc Surg (Torino). 2017;58(5):770-8.

13. del Fresno C, Soler-Rangel L, Soares-Schanoski A, et al. Inflammatory responses associated with acute coronary syndrome up-regulate IRAK-M and induce endotoxin tolerance in circulating monocytes. J Endotoxin Res. 2007;13(1):39-52.

14. Ruan ZB, Fu XL, Li W, et al. Effect of notch1,2,3 genes silicing on NF-kappaB signaling pathway of macrophages in patients with atherosclerosis. Biomed Pharmacother. 2016;84:666-73.

15. Jamil K, Jayaraman A, Ahmad J, et al. TNF-alpha -308G/A and -238G/A polymorphisms and its protein network associated with type 2 diabetes mellitus. Saudi J Biol Sci. 2017;24(6):1195-203.

16. Saxena M, Srivastava N, Banerjee M. Association of IL-6, TNF-alpha and IL-10 gene polymorphisms with type 2 diabetes mellitus. Mol Biol Rep. 2013;40(11):6271-9.

17. Pushkov AA, Blagodatskikh KA, Nikitin AG, et al. Polymorphic markers Ala455Val of the THBD gene and Arg353Gln of the F7 gene and association with unfavorable outcomes of coronary atherosclerosis in patients with a history of acute ischemic heart disease. Genetika. 2011;47(10):1386-92. (In Russ.)